The clinical data of a patient with differentiated thyroid carcinoma(DTC)who developed physiological thymic uptake after postoperative iodine-131(131I)therapy were analyzed,and the 3-year follow-up changes in the patient's condition were reviewed.Combined with the literatures and the diagnosis and treatment process,the causes of possible false positives in whole-body scans after iodine therapy for DTC and the mechanism,clinical features,and identification methods of benign thymic 131I uptake were discussed to improve clinicians' understanding and diagnostic ability regarding such conditions and avoid unnecessary multiple iodine treatments.The patient,a 28-year-old female,showed mediastinal imaging after the first 131I treatment,with more pronounced mediastinal iodine uptake during the second treatment.SPECT/CT localized the uptake to enlarged thymus tissue.The stimulated thyroglobulin(Tg)levels before two 131I treatments were high but gradually decreased.Apart from thymic uptake,no other examination evidence suggested DTC metastases.Subsequent follow-up for 3 years showed no pathological changes in the thymus,confirming physiological thymic uptake.Thymic 131I uptake is a common cause of false-positive whole-body scans in post-thyroidectomy patients.When post-131I therapy whole-body imaging shows only mediastinal uptake,especially in the young patients undergoing multiple 131I treatments where thymic 131I uptake intensity increases with successive treatments,even with elevated Tg levels,comprehensive use of imaging results such as SPECT/CT is essential to determine if it is normal thymus,thereby avoiding unnecessary repeated therapies.

Objective To explore the characteristics and influencing factors of taste abnormalities in patients with differentiated thyroid cancer(DTC)after 131I treatment.Methods A total of 206 DTC patients who received 131I treatment in the First Affiliated Hospital of Nanchang University from August 2023 to December 2023 were followed up for taste abnormalities,dry mouth,and parotid gland swelling.General clinical data including sex,age,and tumor TNM staging were collected.Based on the presence of taste abnormalities,the patients were divided into abnormal taste group and normal taste group.The differences in general data between the two groups were compared,and multiple logistic regression analysis was used to explore the influencing factors of taste abnor-malities.Results Totally,42.23%of the patients experienced taste abnormalities,including 68 patients with varying degrees of reduced taste,3 patients with a loss of taste,6 patients with taste sensitivity,24 patients with taste hallucinations,and 14 patients with both reduced taste and taste hallucinations.The shortest time for the onset of taste abnormalities was 2 days after 131I treatment,and the longest time was 20 days,with a median time of 7 days;The duration ranged from a minimum of 3 days to a maximum of 60 days,with a median of 14 days.The proportion of dry mouth and parotid gland swelling in patients with abnormal taste was higher than that in those with normal taste,showing statistical significance(P=0.004,0.014,respectively).However,there was no statistical significance in terms of sex age,and tumor TNM stage(P>0.05).Multivariate logistic regression analysis showed that dry mouth and parotid gland swelling were risk factors for taste abnormalities in DTC patients treated with 131I(P=0.007,0.024,respectively).Conclusion Abnormal taste is a common adverse reaction in DTC patients after 131I treatment,typically transient,with a median onset time of 7 days post-treatment and a median duration of 14 days.The primary manifestation is reduced taste,with dry mouth and parotid gland swelling identified as risk factors for its occurrence.

Objective To explore the characteristics and influencing factors of taste abnormalities in patients with differentiated thyroid cancer(DTC)after 131I treatment.Methods A total of 206 DTC patients who received 131I treatment in the First Affiliated Hospital of Nanchang University from August 2023 to December 2023 were followed up for taste abnormalities,dry mouth,and parotid gland swelling.General clinical data including sex,age,and tumor TNM staging were collected.Based on the presence of taste abnormalities,the patients were divided into abnormal taste group and normal taste group.The differences in general data between the two groups were compared,and multiple logistic regression analysis was used to explore the influencing factors of taste abnor-malities.Results Totally,42.23%of the patients experienced taste abnormalities,including 68 patients with varying degrees of reduced taste,3 patients with a loss of taste,6 patients with taste sensitivity,24 patients with taste hallucinations,and 14 patients with both reduced taste and taste hallucinations.The shortest time for the onset of taste abnormalities was 2 days after 131I treatment,and the longest time was 20 days,with a median time of 7 days;The duration ranged from a minimum of 3 days to a maximum of 60 days,with a median of 14 days.The proportion of dry mouth and parotid gland swelling in patients with abnormal taste was higher than that in those with normal taste,showing statistical significance(P=0.004,0.014,respectively).However,there was no statistical significance in terms of sex age,and tumor TNM stage(P>0.05).Multivariate logistic regression analysis showed that dry mouth and parotid gland swelling were risk factors for taste abnormalities in DTC patients treated with 131I(P=0.007,0.024,respectively).Conclusion Abnormal taste is a common adverse reaction in DTC patients after 131I treatment,typically transient,with a median onset time of 7 days post-treatment and a median duration of 14 days.The primary manifestation is reduced taste,with dry mouth and parotid gland swelling identified as risk factors for its occurrence.